Christoph Lengauer has contributed to the development of 10 FDA-approved cancer medicines. Christoph is Chief Scientific Officer and a co-founder of Curie.Bio, where he and his team co-pilot seed-stage companies to help founders to achieve series A.

Prior to Curie, Christoph ideated, founded, and built several life science companies as Partner at Third Rock Ventures, including Blueprint Medicines, Relay Therapeutics, Thrive, Celsius Therapeutics, and MOMA Therapeutics.

Prior to joining biotech, Christoph was global head of oncology drug discovery at Sanofi and senior unit head of oncology discovery at Novartis. He has been an Associate Professor at the Johns Hopkins University School of Medicine, where he was involved in the identification of several cancer driver genes including PIK3CA and BRAF. As part of his research in Dr. Bert Vogelstein’s lab, Christoph discovered that all cancers are genetically unstable, which explains the molecular heterogeneity of cancer and why cancers develop resistance to drugs. He has authored more than 100 scientific articles published in top-tier scientific journals, including Cell, Nature, and Science. Christoph studied human genetics in Salzburg, Austria and obtained a Ph.D. in biology from the University of Heidelberg, Germany.